Page 23 - Read Online

Page 14 of 14 Di Raimo et al. J Cancer Metastasis Treat 2018;4:54 I http://dx.doi.org/10.20517/2394-4722.2018.50

associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy. J Surg
Oncol 2018; doi: 10.1002/jso.25125.
177. Kucera R, Topolcan O, Fiala O, Kinkorova J, Treska V, et al. The role of TPS and TPA in the diagnostics of distant metastases. Anticancer
Res 2016;36:773-7.
178. Tang SS, Gui GP. Biomarkers in the diagnosis of primary and recurrent breast cancer. Biomark Med 2012;6:567-85.
179. Mariani L, Miceli R, Michilin S, Gion M. Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their
diagnostic accuracy for the detection of tumour recurrences. Biomarkers 2009;14:130-6.
180. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, et al. Circulating tumor cells and response to chemotherapy in
metastatic breast cancer: SWOG S0500. J Clin Oncol 2014;32:3483-9.
181. Larsson AM, Jansson S, Bendahl PO, Levin Tykjaer Jörgensen C, Loman N, et al. Longitudinal enumeration and cluster evaluation of
circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational
trial. Breast Cancer Res 2018;20:48.
182. Lu YJ, Wang P, Wang X, Peng J, Zhu YW, et al. The significant prognostic value of circulating tumor cells in triple-negative breast cancer: a
meta-analysis. Oncotarget 2016;7:37361-9.
183. Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell
2013;23:573-81.
184. Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, et al. Use of biomarkers to guide decisions on systemic therapy for
women with metastatic breast cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol 2015;33:2695-704.
185. Ellsworth RE, Blackburn HL, Shriver CD, Soon-Shiong P, Ellsworth DL. Molecular heterogeneity in breast cancer: State of the science and
implications for patient care. Semin Cell Dev Biol 2017;64:65-72.
186. Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a
prospective, multicenter trial. Breast Cancer Res Treat 2010;124:403-12.
187. Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, et al. Trastuzumab decreases the incidence of clinical relapses in patients
with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II
study. Ann Oncol 2012;23:1744-50.
188. Paoletti C, Muñiz MC, Thomas DG, Griffith KA, Kidwell KM, et al. Development of circulating tumor cell-endocrine therapy index in
patients with hormone receptor-positive breast cancer. Clin Cancer Res 2015;21:2487-98.
189. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer
Cell 2014;25:282-303.
190. Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in
breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010;16:2634-45.
191. Bardelli A, Pantel K. Liquid biopsies, what we do not know (yet). Cancer Cell 2017;31:172-9.